Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1011.1 + mRNA-1011.2 + mRNA-1012.1
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1011.1 + mRNA-1011.2 + mRNA-1012.1 is a combination of messenger RNA (mRNA) drug substances developed by Moderna as a next-generation seasonal influenza vaccine. This specific combination serves as the updated formulation of Moderna's quadrivalent influenza vaccine candidate, mRNA-1010, and is also the influenza component of the COVID-19/Influenza combination vaccine, mRNA-1083. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver mRNA sequences encoding the hemagglutinin (HA) proteins of four seasonal influenza strains: Influenza A (H1N1 and H3N2) and Influenza B (Victoria and Yamagata lineages). By encoding the HA protein, the vaccine aims to elicit neutralizing antibodies and T-cell responses to prevent infection and severe disease caused by seasonal flu. The updated formulation (incorporating mRNA-1011 and mRNA-1012 components) was designed to improve the immune response against Influenza B strains compared to the first-generation mRNA-1010.
- Other names
- Moderna seasonal influenza vaccineupdated mRNA-1010
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-1011.1 + mRNA-1011.2 + mRNA-1012.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1011.1 + mRNA-1011.2 + mRNA-1012.1.